No headlines found.
Globe Newswire (Tue, 25-Nov 6:30 AM ET)
embecta Announces Quarterly Cash Dividend
Globe Newswire (Tue, 25-Nov 6:00 AM ET)
embecta announces changes to Board of Directors
Globe Newswire (Mon, 17-Nov 5:00 PM ET)
embecta Announces Major New Commitment to Direct Relief on World Diabetes Day
Globe Newswire (Fri, 14-Nov 6:30 AM ET)
embecta to Report Fiscal Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Tue, 11-Nov 5:00 PM ET)
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Embecta Corp. trades on the NASDAQ stock market under the symbol EMBC.
As of December 9, 2025, EMBC stock price climbed to $11.11 with 694,671 million shares trading.
EMBC has a beta of 0.74, meaning it tends to be less sensitive to market movements. EMBC has a correlation of 0.06 to the broad based SPY ETF.
EMBC has a market cap of $650.08 million. This is considered a Small Cap stock.
Last quarter Embecta Corp. reported $264 million in Revenue and $.50 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.04.
In the last 3 years, EMBC traded as high as $36.64 and as low as $9.20.
The top ETF exchange traded funds that EMBC belongs to (by Net Assets): IJR, VTI, IWM, VB, VXF.
EMBC has underperformed the market in the last year with a price return of -39.1% while the SPY ETF gained +13.6%. EMBC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.1% and -23.1%, respectively, while the SPY returned +5.6% and +2.1%, respectively.
EMBC support price is $10.70 and resistance is $11.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EMBC shares will trade within this expected range on the day.